HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.